Drug Database
FA

Factor VIII (Recombinate / rAHF, Baxter / rurioctocog alpha)

✓ Approved

Baxter International, Inc. · F8 · Recombinant Proteins

What is Factor VIII?

Factor VIII is a recombinant proteins developed by Baxter International, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesRecombinate, rAHF, Baxter, rurioctocog alpha
CompanyBaxter International, Inc.
Drug ClassRecombinant Proteins, Cell-based Therapies
Molecular TargetF8
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Baxter International, Inc.

Mechanism of Action

Molecular Targets

Factor VIII acts on 1 molecular target:

F8coagulation factor VIII (AHF, FVIII)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

Factor VIII is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersFactor VIII deficiency✓ Approved

Related Research Articles

PubMedFrontiers in public health2026-09-20

Factors and a configurational pathway associated with lower turnover intention among high-level medical professionals in county-level hospitals in China: a multicenter cross-sectional study.

Dong Shuxin S, Tai Qiuyuan Q, Yao Yiming Y, Shen Junlong J et al.

This study developed a context-specific framework of perceived conditions related to lower turnover intention among high-level medical professionals in county-level hospitals and examined the configurational pattern associated with a high retention-oriented score. A multicenter cross-sectional study combined three Delphi rounds, psychometric evaluation, and fuzzy-set qualitative comparative analysis (fsQCA). The Delphi process progressed from 33 items in round 1-37 in round 2 and 34 assessed in round 3, with 33 retained for the survey. From July 2024 to February 2025, online and paper questionnaires were distributed in 10 county-level public hospitals in Jiangsu Province. Of 635 questionnaires distributed, 611 were returned and 579 were valid. The sample was randomly split for exploratory factor analysis (EFA; n = 289) and confirmatory factor analysis (CFA; n = 290). fsQCA used the full sample, a frequency threshold of 10, consistency of 0.85, and proportional reduction in inconsistency (PRI) of 0.70. Thirty experts participated in Delphi round 1 and 29 in rounds 2 and 3 after one expert retired. The final 31 condition items showed high internal consistency (alpha = 0.971), suggesting both reliability and possible redundancy. Parallel analysis in the EFA half-sample suggested two factors, whereas a theory-constrained five-factor solution remained interpretable. In the CFA half-sample, the correlated five-factor model fit was marginal (Satorra-Bentler chi-square = 1350.48, df = 424, CFI = 0.903, TLI = 0.893, RMSEA = 0.087, 90% CI 0.082-0.092, SRMR = 0.042) and was similar to the second-order and bifactor models. No condition met the 0.90 necessity threshold. The corrected truth-table analysis identified one high-score configuration, PD*IES*CIS*OIE (consistency = 0.953; PRI = 0.917; coverage = 0.631). PD and CIS were core present conditions; IES and OIE were peripheral present conditions; IEPS was not included. A single sufficient configuration combined favorable perceptions of personal development, institutional/environmental support, compensation/incentive support, and organizational/interpersonal empowerment. The result does not support multiple substitutable pathways. Because the outcome was a retention-oriented score derived from a turnover-intention measure, the findings concern lower turnover intention rather than directly observed retention. The cross-sectional, individual-level results indicate associations and should not be interpreted causally or at the hospital level.

PMID 42763469
Read full article →
PubMedJournal of research in nursing : JRN2026-09-20

Psychometric properties of the Persian version of Pressure Ulcer Management Self-Efficacy Scale for nurses.

Mohammadzade Sarhadi Sajjad S, Najafi Fereshteh F, Fendereski Afsaneh A, Sharifi Simin S

Pressure ulcers remain a major clinical challenge, and nurses' self-efficacy is essential for their prevention and management. The Pressure Ulcer Management Self-Efficacy Scale (PUM-SES) for nurses was developed to assess this competency. This study aimed to translate, culturally adapt and validate the Persian version of the PUM-SES (PUM-SES-P) among Iranian nurses. This three-phase study began with forward and back translation. In phase two, face and content validity were evaluated by 10 nurses and 15 experts, respectively, and construct validity and reliability were assessed among 200 and 30 nurses. In phase three, criterion-related and convergent validity were evaluated among 100 nurses. Content validity indices were favourable (content validity index = 0.97, content validity ratio = 0.90), and factor analysis supported a four-factor structure. The scale showed high internal consistency (α = 0.91) and acceptable test-retest reliability (r = 0.89). Correlations with General Self-Efficacy Scale (r = 0.88) and Attitude towards Pressure Ulcer Prevention instrument (r = 0.77, p < 0.001) supported validity. The PUM-SES-P appears to be a valid, reliable instrument for assessing pressure ulcer self-efficacy among Iranian nurses in this sample, offering a potentially useful resource for nurse educators and unit managers. Further validation in larger, more diverse samples is recommended before broader clinical application.

PMID 42763473
Read full article →
PubMedMolecular psychiatry2026-09-20

Targeting the dopaminergic midbrain with precision 7-Tesla biofeedback training in depression: A proof-of-principle randomized controlled trial.

Morris Laurel S LS, Beltrán Jacqueline M JM, Kvamme Timo L TL, Chowdhury Avijit A et al.

The significant heterogeneity of major depressive disorder (MDD) requires the development of interventions that directly target underlying cognitive or neurobiological mechanisms. This work tested the efficacy of self-modulation of the dopaminergic midbrain with high-field 7-Tesla functional MRI biofeedback in a randomized, controlled, proof-of-principle trial that targeted motivation regulation. A total of N = 62 unmedicated participants (MDD and healthy controls) were randomized to receive either Active or Sham 7-Tesla functional MRI biofeedback and completed clinical assessments pre- and up to 30-days post-training. Factor analysis of clinical symptom change revealed a single latent clinical improvement factor that was significantly improved in the Active MDD compared to the Sham MDD group, immediately post-training (β = 15.85, t = 2.31, p = 0.03), and at 24-hours post-training (β = 22.84, t = 2.45, p = 0.02); effects were diminished and no longer significant at 7-day and 30-day follow-ups. Results of specific phenotypic clinical analysis revealed that depressed mood (F = 5.04, p = 0.029) and negative affect (F = 5.21, p = 0.027), but not positive affect, were most improved by the Active biofeedback intervention. Active biofeedback training engaged functional coupling over time between the VTA and the lateral frontal cortex in the MDD group (F = 6.03, p = 0.017), and greater overall VTA regulation was associated with clinical improvement (R = 0.268, p = 0.048). Together, these results indicate the potential utility of dopaminergic midbrain-based biofeedback training for improvement of mood and negative affect in MDD.

PMID 42763338
Read full article →
PubMedCase reports in ophthalmological medicine2026-09-20

Netarsudil-Induced Honeycomb Keratopathy in an Eye With Iridocorneal Endothelial Syndrome.

Ferguson Alina N AN, Bojikian Karine Duarte KD, Nguyen Minh T MT

To describe a case of netarsudil-associated honeycomb keratopathy in a patient with iridocorneal endothelial (ICE) syndrome. A 43-year-old male with a history of Cogan-Reese variant ICE syndrome presented with ocular irritation, foreign body sensation, blurred vision, photosensitivity, and discharge in the right eye 2 weeks after initiating topical netarsudil 0.02% for secondary angle-closure glaucoma. Slit lamp exam and anterior segment optical coherence tomography demonstrated diffuse reticular epithelial cysts, consistent with netarsudil-induced honeycomb keratopathy. Three weeks after netarsudil cessation, slit lamp exam showed complete resolution of corneal edema. Endothelial cell dysfunction in ICE syndrome may be a risk factor for patients to develop reversible netarsudil-induced honeycomb keratopathy. Ophthalmologists should exercise caution when prescribing netarsudil for glaucoma management in patients with pre-existing corneal pathologies, including those with ICE syndrome.

PMID 42763536
Read full article →
PubMedCureus2026-09-20

Edinburgh University Solution of Lime (EUSOL) Versus Platelet-Derived Growth Factor Dressing for Wound Contraction in Grade II Wagner Diabetic Foot Ulcers: A Randomized Controlled Trial.

Batool Fizza F, Munawwar Fasiha F, Shaukat Hassan H, Janjua Atif A AA et al.

Background Diabetic foot ulcers remain a leading cause of lower-limb amputation worldwide, and wound management is especially difficult in resource-limited settings where older antiseptic agents such as Edinburgh University Solution of Lime (EUSOL) are still in routine use. This trial compared EUSOL dressing with platelet-derived growth factor (PDGF) dressing for wound contraction in Grade II Wagner diabetic foot ulcers. Methodology In this randomized controlled trial, 120 patients aged 30 to 70 years with Grade II Wagner diabetic foot ulcers were assigned in a 1:1 ratio to daily EUSOL dressing or PDGF dressing applied every fourth day for four weeks after debridement and infection control. Wound healing was defined as a reduction in ulcer area of at least 50% from baseline at four weeks. A multivariate logistic regression model examined treatment group, age, sex, body mass index (BMI), diabetes duration, and antidiabetic therapy as predictors of healing. Results Patients averaged 49.8 ± 10.2 years of age and a BMI of 27.1 ± 3.45 kg/m²; 58.3% were male. Seventy-eight patients (65%) used oral hypoglycemic agents alone, while 42 (35%) required insulin. Seventy-one patients (59.2%) had diabetes for more than 10 years. Wound contraction occurred in 20 of 60 (33.3%) patients on EUSOL versus 44 of 60 (73.3%) on PDGF (P < 0.001). PDGF remained a strong independent predictor of healing on multivariate analysis (adjusted odds ratio (OR) 6.14, 95% confidence interval (CI) 2.69-14.02, P < 0.001), as did insulin therapy (adjusted OR 2.48, 95% CI 1.10-5.59, P = 0.028). Conclusions PDGF dressing produced substantially better wound contraction than EUSOL in Grade II diabetic foot ulcers, an effect that persisted after adjustment for the usual confounders. Insulin use was independently linked to better healing, pointing to glycemic management as a modifiable lever alongside dressing choice. Confirmation in multicenter trials with longer follow-up, blinded outcome assessment, and cost data would strengthen the case for wider adoption of PDGF-based dressings in similar settings.

PMID 42763719
Read full article →
PubMedJournal of urban health : bulletin of the New York Academy of Medicine2026-09-20

Discretion and Variation in Drug‑Related Federally Assisted Housing Policies Across Public Housing Authorities in Overdose-Impacted Jurisdictions.

Bedoya Michelle L ML, Kennedy-Hendricks Alene A

Public housing authorities (PHAs) apply federal drug-related eligibility and termination criteria but retain discretion in specifying key provisions. We reviewed 36 written policy documents from 19 PHAs serving overdose-impacted metropolitan and micropolitan jurisdictions in 18 states and Washington, D.C. Jurisdictions were selected purposively based on local overdose rates and metropolitan or micropolitan classification. We coded six components spanning eviction and criminal activity lookback periods; definitions of current drug use; termination standards; and whether substance use disorder (SUD) treatment could mitigate exclusions and termination decisions. Criminal activity lookback periods ranged from 18 months to 10 years, and definitions of current drug use and termination criteria varied or were undefined. Most policies permitted SUD treatment as a mitigating factor, but some did not. Variation in written policies within a shared federal framework may contribute to structural barriers to stable housing for people with SUD, with implications for recovery and overdose prevention.

PMID 42763353
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Factor VIII